Comparison between an Iranian Traditional Medicine pharmaceutical product and fatty substance on reduction of liver and gallbladder disturbing shadow in myocardial perfusion imaging

Comparison between an Iranian Traditional Medicine pharmaceutical product and fatty substance on reduction of liver and gallbladder disturbing shadow in myocardial perfusion imaging with Tc-MIBI

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016071215860N4

Enrollment

Registered

2016-10-27

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemic heart diseases. Atherosclerotic heart disease

Interventions

Intervention 1: Intervention group: Drinking 200 cc of a pharmaceutical product (syrup) of Iranian traditional medicine, 10 min after radiopharmaceutical administration. . Intervention 2: Control gro

Diagnosis

Intervention group: Drinking 200 cc of a pharmaceutical product (syrup) of Iranian traditional medicine, 10 min after radiopharmaceutical administration. .

Control group: using 100 gr of fatty food , 10 min after radiopharmaceutical administration.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who refer by cardiologists to Nuclear medicine center of Imam Khomeini hospital for performing perfusion scan; patients between 18 to 70 years; Hyperlipidemic patients; Unwillingness to use fat; Feeling of nausea when patients eat fat Exclusion criteria: Patients who suffer from certain diseases such as heart disease or liver and bile ducts disorders; Pregnancy; Known active infection; An identified blood laboratory abnormalities at baseline; Peptic ulcer or biliary obstruction or gallstones

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of clearing the intrusive activity of the liver. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: Measuring Heart/Liver ratio by observation and ratio determination of numeration of the heart to the liver.;Amount of clearing the intrusive activity of the gallbladder. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: easuring Heart/gallbladder ratio.	—

Measure

Time frame

Amount of clearing the intrusive activity of the liver. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: Measuring Heart/Liver ratio by observation and ratio determination of numeration of the heart to the liver.;Amount of clearing the intrusive activity of the gallbladder. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: easuring Heart/gallbladder ratio.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhazaleh Heydarirad

Department of Traditional Medicine, School of Traditional Medicine Shahid Beheshti University of Med

dr.ghazalrad@sbmu.ac.irghazalrad@yahoo.com+98 21887735235

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026